Early onset type 2 diabetes mellitus: a harbinger for complications in later years clinical observation from a secondary care cohort
|
|
- Clara Randall
- 6 years ago
- Views:
Transcription
1 Q J Med 2009; 102: doi: /qjmed/hcp121 Advance Access Publication 4 September 2009 Early onset type 2 diabetes mellitus: a harbinger for complications in later years clinical observation from a secondary care cohort S.H. SONG 1 and C.A. HARDISTY 2 From the 1 Diabetes Centre, Northern General Hospital, Sheffield and 2 Diabetes Centre, Royal Hallamshire Hospital, Sheffield, UK Received 27 May 2009 and in revised form 9 August 2009 Summary Background: Little is known about the complication burden in later years among early onset type 2 diabetes mellitus (T2DM). Aim: To determine the magnitude of diabetes complications and adequacy of risk factor management and to test the hypothesis that diabetes duration is an important contributing factor to these complications. Design: A cross-sectional study of secondary care diabetes population. Methods: Data on glycaemic control, cardiovascular risk factors (overweight/obesity, hypertension, dyslipidaemia), cardiovascular disease (CVD) and microvascular complications among those diagnosed before (early onset) and after (later onset) 40 years of age at different diabetes durations (<10, and >20 years) were analysed. Results: A total of 2733 subjects were identified, of which 527 had diabetes diagnosed below the age of 40 years. By the sixth decade of life, early onset cohort experienced high complication burden (CVD: 37.2%, retinopathy: 59.3% and Introduction The global burden of type 2 diabetes mellitus (T2DM) is significant and rising, with most of the increase occurring in the last two decades. The worldwide prevalence of diabetes in adults is expected to increase from 5% to 6.2% between 2003 and While most of the rise in the neuropathy: 53.1%). Complication prevalence increased with diabetes duration but the increment rate was greater among early onset cohort. Compared with those diagnosed after 40, early onset cohort experienced similar burden of microvascular complications years earlier. Diabetes duration was a significant predictor for microvascular and CVD complications. Prevalence of CVD risk factors was high (80 93%) regardless of the age of diagnosis and diabetes duration. Early onset subjects were more likely to have poorer glucose control (70 78%), untreated hypertension (26.3%) and a substantial number did not receive statin treatment for primary prevention (34.8%). Discussion: Early onset T2DM subjects are at substantial risk of developing diabetes complications in later years but at an earlier stage than later onset cohort and prolonged exposure to adverse diabetic milieu is an important contributing factor. Management of risk factors for diabetes complications was inadequate among early onset subjects. prevalence of T2DM occurs in middle-aged and elderly, it is becoming more common among younger patients, including children and adolescents. The fall in age of onset of T2DM is driven by increasing obesity in the younger age group. This is supported by the observation of an inverse relationship between obesity and age of diagnosis of T2DM. 2 Of concern is the fact that obesity has Address correspondence to Dr S.H. Song, Diabetes Centre, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK. soon_song@hotmail.com! The Author Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 800 S.H. Song and C.A. Hardisty increased by 70% in adults aged between 30 and 39 years, thus, making young adults the fastest growing group for obesity and T2DM. 3 We have previously demonstrated that despite the young age, early onset cohort possessed adverse cardiovascular risk profile characterized by multiple risk factor clustering (obesity, hypertension, dyslipidaemia) and suboptimal glycaemic control 4 which mirrored the findings from other studies. 5,6 Given the potential long duration of exposure to this adverse milieu, it is plausible that these young subjects are at risk of developing significant diabetesrelated complications at later stages of their lives. Another possibility is that early diagnosis of T2DM in young subjects confers an inherently aggressive phenotype to develop complications, more so than the later onset cohort. 7 At present, no study has examined long-term outcomes as a function of age of diagnosis of T2DM in the UK. This knowledge will be immensely invaluable to support the argument that intensive clinical management is mandatory in these young diabetics to prevent or reduce future development of complications and the associated morbidity and mortality. This study builds on our previous work and is designed to bridge the existing knowledge gap by addressing these fundamental clinical questions: (i) to determine whether early onset T2DM subjects are at risk of developing future diabetes-related complications; (ii) to determine the magnitude of diabetes-related complications compared with later onset cohort of similar disease duration; (iii) to determine whether diabetes duration and/or lower age of diagnosis is a contributing factor to complication development in early and later onset cohort; and (iv) to determine the adequacy of risk factor management among early vs. later onset cohort. Methods This was a cross-sectional study using secondary care T2DM population and subjects were identified from hospital diabetes register. This electronic diabetes database records clinical details of all subjects with types 1 and 2 diabetes who attend clinics at Northern General Hospital and Royal Hallamshire Hospital for their clinical care. The clinical data were routinely entered into this database each time the diabetic subjects were seen at these clinics. All data relevant to this study were collected in 2008 as the part of the annual audit and service evaluation process within the diabetes department. Those known to have latent autoimmune diabetes in adult (LADA), maturity onset diabetes of the young (MODY), gestational diabetes and secondary diabetes were excluded. Early and later onset T2DM refer to those whose diabetes was diagnosed below and above the age of 40 year, respectively, as defined by the NICE guideline for T2DM 8 and Joint British Socieities-2 guideline. 9 For each patient, data on clinical characteristics, prevalence of microvascular disease (retinopathy and neuropathy) and cardiovascular disease (CVD), which included ischaemic heart disease, peripheral vascular disease and stroke, were collected. Data on microalbuminuria were not available as this test was not routinely performed in the management of T2DM in Sheffield. To assess the impact of diabetes duration on complication outcomes, early and later onset cohort were categorized into three different diabetes durations, namely, <10, and >20 years. All statistical analyses were performed using the Statistical Package for Social Science (SPSS) for Windows (SAS Institute, Cary, NC, USA). Continuous data were expressed as mean and standard deviation (SD), while categorical data were expressed as absolute subject number and percentage. The normality of continuous data distribution was tested to determine the appropriate method for parametric or non-parametric statistical analysis. Mann Whitney U-test and chi-squared ( 2 ) test were used to compare variables between two groups. The 2 -value for the trend was used to determine the significance of trends in frequency across different groups. Logistic regression was used to determine the significance of diabetes duration and age of diabetes onset as a predictor for the development of microvascular and CVD complications. P < 0.05 is considered significant. Results A total of 2733 subjects were included in this study, of which 527 had diabetes diagnosed below the age of 40 years. The clinical characteristics of the study subjects as stratified by diabetes duration are shown in Table 1. The mean age of diagnosis was 32 years and between 50 and 55 years among the early and later onset cohort, respectively. Irrespective of the age of diagnosis and diabetes duration, majority (82 93%) of subjects possessed multiple CVD risk factors (overweight/obese, hypertension, dyslipidaemia). The relationship between diabetes duration and microvascular and CVD complications is shown in Table 2 and Figure 1, while Table 3 shows the prevalence of diabetes complications in relation to mean current age. Among those with shortest diabetes duration (<10 years), the prevalence of complications was higher in later onset cohort.
3 Early onset T2DM 801 Table 1 Clinical characteristics Age of diagnosis <40 years (N = 527) Age of diagnosis >40 years (N = 2206) Diabetes duration (years) < >20 < >20 (n = 227) (n = 155) (n = 145) (n = 1035) (n = 901) (n = 270) Current age (years) 39.8 (6.3) 49.7 (6.5) 62.4 (8.1) 63.7 (10.1) 70.4 (7.9) 75.5 (5.9) Age of diagnosis (years) 32.5 (5.5) 32.9 (5.4) 32.1 (6.9) 55.7 (9.8) 54.1 (7.9) 49.2 (5.8) Diabetes duration (years) 5.9 (2.6) 15.4 (3.0) 28.7 (7.3) 6.5 (2.6) 14.8 (2.7) 24.7 (3.8) Systolic BP (mmhg) (19.5) (18.4) (21.0) (19.9) (20.1) (21.3) Diastolic BP (mmhg) 79.5 (10.7) 75.9 (12.1) 71.6 (8.5) 75.4 (11.6) 72.2 (10.8) 71.1 (12.1) BMI (kg/m 2 ) 34.8 (8.7) 34.9 (6.9) 33.0 (6.6) 33.9 (6.7) 33.0 (6.5) 30.9 (6.1) HbA1c (%) 8.9 (2.0) 9.2 (2.0) 8.9 (1.7) 8.3 (1.9) 8.5 (1.7) 8.3 (1.3) Total chol (mmol/l) 4.7 (1.5) 4.3 (1.3) 4.1 (0.9) 4.2 (1.0) 3.9 (1.0) 3.8 (0.9) HDL (mmol/l) 1.04 (0.28) 1.04 (0.32) 1.19 (0.36) 1.10 (0.33) 1.11 (0.33) 1.15 (0.40) Triglyceride (mmol/l) 2.8 (3.2) 2.7 (3.3) 2.0 (1.2) 2.3 (1.7) 2.1 (2.0) 1.8 (1.2) BMI > 25 (%) 206 (90.7) 149 (96.1) 131 (90.3) 970 (93.7) 834 (92.6) 240 (88.9) Hypertension (%) 128 (56.4) 125 (80.6) 127 (87.6) 861 (83.2) 805 (89.3) 251 (93.0) Dyslipidaemia (%) 184 (81.1) 129 (83.2) 99 (68.3) 792 (76.5) 664 (73.7) 183 (67.8) Two risk factors (%) 187 (82.4) 143 (92.3) 133 (91.7) 954 (92.2) 835 (92.7) 247 (91.5) Values are expressed as mean (SD) unless noted otherwise. BP: blood pressure; HDL: high density lipoprotein; BMI: body mass index. Table 2 Prevalence of diabetes-related complications Age of diagnosis <40 years Age of diagnosis >40 years Diabetes duration (years) < >20 P-value < >20 P-value Macrovascular CVD (%) 19 (8.4) 29 (18.7) 54 (37.2) (31.1) 383 (42.5) 137 (50.7) Ischaemic heart disease (%) 13 (5.7) 21 (13.5) 40 (27.6) (25.4) 291 (32.3) 93 (34.4) Peripheral vascular disease (%) 4 (1.8) 4 (2.6) 19 (13.1) (4.8) 82 (9.1) 43 (15.9) Stroke (%) 3 (1.3) 7 (4.5) 12 (8.3) (5.9) 88 (9.8) 45 (16.7) Microvascular Retinopathy (%) 10 (4.4) 55 (35.5) 86 (59.3) (9.5) 264 (29.3) 150 (55.6) Neuropathy (%) 28 (12.3) 51 (32.9) 77 (53.1) (24.1) 332 (36.8) 136 (50.4) Increasing diabetes duration was associated with higher prevalence of complications irrespective of age of diagnosis. Using diabetes duration <10 years as reference, the rate of increment for microvascular and CVD complications with increasing diabetes duration was greater for those diagnosed below the age of 40 years (Figure 1) to the extent that comparable magnitude of microvascular complications occurred at an earlier age in early onset cohort (Table 3). This occurred years earlier than later onset cohort (retinopathy/neuropathy prevalence of 30 35%: early vs. later onset, 49.7 vs years and retinopathy/neuropathy prevalence of 50 60%: early vs. later onset, 62.4 vs years). At a similar current age (63 years), the prevalence of CVD for early onset cohort with long diabetes duration (mean: 28.7 years) exceeded those of later onset cohort with short diabetes duration (mean: 6.5 years; early vs. later onset; 37.2 vs. 31.1%]. The question as to whether diabetes duration and/ or lower age of diagnosis are predictive factors for the development of diabetes complications among early and later onset cohort is examined by logistic regression analysis and the findings are shown in Table 4. Clearly, diabetes duration was a significant predictor of microvascular and CVD complications for early and later onset cohort and this would be in agreement with the observation summarized in Table 2. In contrast, lower age of diagnosis did not appear to be an important factor. Among early onset cohort, lower age of diagnosis was not associated with the development of complications [CVD: odds ratio (OR) 1.05, P = 0.023; retinopathy: OR 0.99,
4 802 S.H. Song and C.A. Hardisty Figure 1. Magnitude of increment in diabetes-related complications. Table 3 Mean current age and prevalence of diabetes-related complications Age of diagnosis <40 years Age of diagnosis >40 years Diabetes duration (years) < >20 < >20 Mean current age (years) CVD (%) Retinopathy (%) Neuropathy (%)
5 Early onset T2DM 803 Table 4 Logistic regression analysis of diabetes duration and age of diabetes onset as predictor for diabetes-related complications Age of diagnosis <40 years Age of diagnosis >40 years Complications OR (95% CI) P-value OR (95% CI) P-value Diabetes duration CVD 1.09 ( ) ( ) Retinopathy 1.13 ( ) ( ) Neuropathy 1.08 ( ) ( ) Age of diabetes onset CVD 1.05 ( ) ( ) Retinopathy 0.99 ( ) ( ) 0.04 Neuropathy 1.07 ( ) ( ) 0.89 Table 5 Management of risk factors for diabetes-related complications Age diagnosis <40 years Age diagnosis >40 years P-value CVD risk management No. of CVD + at least two risk factors without statin treatment (%) 109 (34.8) 414 (39.0) No. of CVD + hypertension without anti-hypertensive treatment (%) 86 (26.3) 185 (16.8) Glycaemic control Mean HbA1c (%) Diabetes duration <10 years 8.9 (2.0) 8.3 (1.9) years 9.2 (2.0) 8.5 (1.7) >20 years 8.9 (1.7) 8.3 (1.3) Proportion with HbA1c >7.5% (%) Diabetes duration <10 years 172 (71.4) 503 (58.9) years 132 (77.4) 682 (68.9) 0.01 >20 years 139 (77.9) 199 (66.3) Values are expressed as mean (SD) unless noted otherwise. P = 0.80; neuropathy: OR 1.07, P = 0.004]. Except for retinopathy (OR 0.97, P = 0.04), lower age of diagnosis was also not significantly associated with diabetes complications in later onset cohort (CVD: OR 1.03, P = 0.001; neuropathy: OR 0.99, P = 0.89). This finding is in contrast with those of diabetes duration which has been shown to be a consistent significant predictive factor regardless of the nature of complications in early and later onset cohort. Based on this pattern of observations, it is unlikely that lower age of diagnosis is a significant predictor of diabetes complications, particularly among those whose diabetes were diagnosed at a young age. The adequacy of glycaemic control and CVD primary prevention management is shown in Table 5. Early onset T2DM cohort had significantly poorer glycaemic control across all diabetes durations and higher proportion of untreated hypertension compared with those diagnosed later. Despite having at least two co-existing cardiovascular risk factors (obesity, hypertension, dyslipidaemia), a substantial number of early and later onset subjects did not receive statin treatment as recommended by the UK guidelines. 8,9 Discussion The principal clinical concern with T2DM subjects diagnosed at a young age is the potential development of clinically significant complications and the associated morbidity and mortality at an earlier stage of life than those diagnosed later. Various studies have provided definitive evidence for unfavourable glycaemic and cardiovascular risk profile in young T2DM, but the crucial link to subsequent occurrence and magnitude of micro- and macrovascular complications is lacking. In this study, we have addressed this knowledge gap for the first time in a UK population. We demonstrated that early onset T2DM is not a benign condition, but a high-risk phenotype to develop significant future
6 804 S.H. Song and C.A. Hardisty microvascular and CVD complications at a younger age than later onset cohort. Exposure to adverse diabetic milieu in the early stages of the natural history of T2DM is an important contributing factor to this phenomenon. Our novel findings are clinically relevant as it can potentially change the misperception of the risk status of early onset T2DM subjects and positively influence its management, particularly the intensiveness of risk factor and glycaemic intervention. Although the absolute risk for diabetes complications is small among early onset subjects with short diabetes duration as manifested by the low complication prevalence, these subjects, however, have an extremely high lifetime risk by virtue of the long disease duration and exposure to the hyperglycaemic environment and its associated atherogenic risk factors. Our findings serve to illustrate the importance of understanding the fundamental conceptual difference between absolute and lifetime risk in clinical practice. Comparable complication burden occurred at an earlier stage for early onset cohort indicating that these subjects are more likely to experience higher complication rate than later onset cohort at similar chronological age. Obesity is known to accentuate the lifetime risk for CVD in diabetes. 10 In our study, vast majority (>90%) of early onset subjects with short diabetes duration were either overweight or obese. It is evident from our findings that current age is a poor barometer to gauge the risk of developing future complications in young T2DM subjects. Recent evidence is accumulating to support the concept of cardiometabolic memory where intensive management of glycaemia and CVD risk factors during early stages of T2DM can lead to subsequent reduction in micro- and macrovascular complications much later in the course of disease. 11,12 Translating this concept into clinical practice is of utmost importance in the management of those whose diabetes is diagnosed at a young age given their adverse baseline clinical characteristics and high complication burden in the future. Worryingly, our observation indicates that risk factor intervention is less rigorous for these subjects including those with short diabetes duration. Contributing factors include misconception of young diabetics as being low risk, lack of robust randomized controlled trial evidence and reluctance to expose these subjects to potentially lifelong treatments. 13 It is known that a significant proportion of people with diabetes remain undetected. 14 Screening for T2DM can identify patients at an earlier stage of the disease who might benefit from intensive diabetes control and treatment of adverse risk factors. In the UK, the Department of Health recently introduced the National Health Service Health Check programme for individuals aged between 40 and 74 years which involved checking blood glucose to detect new cases of diabetes as well as screening for risk factors predisposing to CVD. 15 Since diabetogenic and atherogenic risk factors are present in high-risk young adults, it can be argued that screening should also include those aged <40 years. This debate is supported by the findings of a recent study using the ADDITION Cambridge cohort to assess the magnitude of CVD risk reduction achieved through early intensive pharmacological intervention in T2DM subjects aged >40 years diagnosed through screening. 16 Majority of the screen-detected subjects (mean age of diagnosis: 62 years) were overweight or obese, hypertensive and dyslipidaemic, the prevalence of these risk factors were similar to our early onset cohort (mean age of diagnosis: 32 years). Failure to detect T2DM in the young represents a missed opportunity to improve the health of this vulnerable but important segment of the population. There is an evidence to suggest that early onset diabetes is associated with an increased risk for complications compared with later onset diabetes 6 and that the development and progression of complications might be more rapid in early onset disease. 7 Various hypotheses have been proposed including longer lifetime exposure to adverse diabetic milieu and early onset T2DM as an inherently more aggressive metabolic phenotype. Our findings support the former hypothesis and this is in agreement with the observations from other studies. 17,18 We did not find any consistent association between lower age of diabetes onset with greater diabetes complications, particularly among early onset subjects. The strength of our analysis included the incorporation of a range of matched diabetes durations up to >20 years which allowed sufficient time for complications to occur particularly for CVD. Nevertheless, there are evidence to support the hypothesis that early onset diabetes may be an inherently aggressive phenotype. A recent study demonstrated the prevalence and severity of retinopathy was higher in early onset cohort compared with later onset cohort of similar disease duration. 19 Other studies examined the effect of physical activity on insulin resistance and serum CVD risk markers and after 3 months of exercise, there was no improvement in these parameters. 20,21 From the clinical perspective, all these evidence strengthen the conviction that prevention and early detection of diabetes among the young should be a priority in public health strategy.
7 Early onset T2DM 805 There are limitations to this study. First, our observation may not be extrapolated to the majority of T2DM subjects whose care is delivered in the community as this study cohort is based on a secondary care population. While it could be argued that early onset subjects with worse glycaemic and CVD risk profile are preferentially referred to hospital clinics, our observation is consistent with those of large population-based epidemiological studies. 2,6,22 Second, the cross-sectional nature of this study precludes the opportunity to determine the absolute levels of risk factors measured in early onset subjects that predict diabetes-related complications in later years. Third, the totality of microvascular complication burden could not be determined as there was no complete data on microalbuminuria. Finally, there was no data on mortality and end-stage complications such as blindness, dialysis and amputations. In conclusion, T2DM is a high-risk condition regardless of age of onset. Significant risks reside in the future development of premature micro- and macrovascular complications among those who were diagnosed at a young age. This phenomenon presents major governmental, societal, public health and medical challenges to promote healthy lifestyle in the general population to prevent diabetes, screening appropriate individuals including the young for early detection of diabetes and timely optimization of medical care to prevent or reduce the onset of complications. Future research should focus on long-term longitudinal observation of young people with diabetes to ascertain its natural history and effective choice of treatment to prevent or reduce complication-associated morbidity and mortality. Acknowledgements We would like to thank Teresa Dodd for her excellent and helpful technical assistance in extracting the relevant data from the electronic diabetes database for this study. Conflict of interest: None declared. References 1. Sicree R, Shaw JE, Zimmet PZ. Global and social implications of the diabetes epidemic. Nature 2001; 414: Hillier TA, Pedula KL. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care 2001; 24: Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, et al. Diabetes trends in the US: Diabetes Care 2000; 23: Song SH, Hardisty CA. Cardiovascular risk profile of early and later onset type 2 diabetes. Practical Diabetes Int 2007; 24: Hatunic M, Burns N, Finucane F, Mannion C, Nolan JJ. Contrasting clinical and cardiovascular risk status between early and later onset type 2 diabetes. Diabetes Vasc Dis Res 2005; 2: Hillier TA, Pedula KL. Complications in young adults with early onset type 2 diabetes: losing the relative protection of youth. Diabetes Care 2003; 26: Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007; 369: National Institute for Health and Clinical Excellence. Type 2 diabetes. The management of type 2 diabetes. NICE clinical guideline. London, NICE, British Cardiac Society, British Hypertension Society, Diabetes UK, Heart UK, Primary Care Cardiovascular Society, Stroke Society. Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl. V):v Fox CS, Pencina MJ, Wilson PWF, Paynter NP, Vasan RS, D Agostino RB. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study. Diabetes Care 2008; 31: Holman RR, Paul SJ, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: Gaede P, Lund-Andersen H, Parving HH, Pederson O. Effect of multi-factorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: Song SH, Hardisty CA. Early-onset type 2 diabetes mellitus: an increasing phenomenon of elevated cardiovascular risk. Expert Rev Cardiovasc Ther 2008; 6: Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16: Department of Health. Putting prevention first. Vascular checks: risk assessment and management. London, DH, Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, Williams KM, Barling RS, Butler R, et al. How much tight cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Diabet Med 2008; 25: Paskov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006; 296: Chuang LM, Soegando S, Soewando P, Young-Seol K, Mohamed M, Dalisay E, et al. Comparisons of the outcomes on control, type of management and complications status in early onset and late onset type 2 diabetes in Asia. Diabetes Res Clin Pract 2006; 71: Wong J, Molyneaux L, Constantino M, Twigg SM, Yue DK. Timing in everything: age of onset influences long term retinopathy risk in type 2 diabetes, independent of traditional risk factors. Diabetes Care 2008; 31: Burns N, Finucane FM, Hatunic M, Gilman M, Murphy M, Gasparro D, et al. Early-onset type 2 diabetes in obese white
8 806 S.H. Song and C.A. Hardisty subjects is characterized by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia 2007; 50: Hatunic M, Finucane F, Burns N, Gasparro D, Nolan JJ. Vascular inflammatory markers in early-onset obese and type 2 diabetes subjects before and after three months aerobic exercise training. Diabetes Vasc Dis Res 2007; 4: Aquilar-Salinas CA, Rojas R, Gomez-Perez FJ, García E, Valles V, Ríos-Torres JM, et al. Prevalence and characteristics of early-onset type 2 diabetes in Mexico. Am J Med 2002; 113:
Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationMetabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya
Original Article Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study Alshkri MM 1, Elmehdawi RR 2 1 Benghazi Diabetes Center. 2 Medical Department, Faculty of Medicine,
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationPrevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine
Prevention of complications: are we winning or losing the battle Naveed Sattar Professor of Metabolic Medicine Duality of Interest Declaration Consultant or speaker for: Amgen, AstraZeneca, Boehringer
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationThe State of Play of Diabetes Indicators
The State of Play of Diabetes Indicators South Australian and National Information Catherine Chittleborough Janet Grant Anne Taylor April 2003 Diabetes Clearing House Population Research and Outcome Studies
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes
More informationHemoglobin A1C and diabetes diagnosis: The Rancho Bernardo Study
Diabetes Care Publish Ahead of Print, published online October 16, 2009 Hemoglobin A1c and diabetes Hemoglobin A1C and diabetes diagnosis: The Rancho Bernardo Study Running Title: Hemoglobin A1c and diabetes
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationWhy Do We Care About Prediabetes?
Why Do We Care About Prediabetes? Complications of Diabetes Diabetic Retinopathy Leading cause of blindness in adults 1,2 Diabetic Nephropathy Leading cause of Kidney failure Stroke 2- to 4-fold increase
More informationSerum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting glucose: The Rancho Bernardo Study
Diabetes Care Publish Ahead of Print, published online June 9, 2009 Serum uric acid and incident DM2 Serum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationSurvey Scottish Diabetes. Survey Monitoring Group
Scottish Diabetes Survey 2009 Scottish Diabetes Survey Monitoring Group 2 Foreword The Scottish Diabetes Survey is now in its ninth year. This 2009 Survey, as with previous versions, continues to demonstrate
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationDIABETES. A growing problem
DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationNormal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis
CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More information04-Sep-17. INERTIA a failure to initiate or modify treatment in a timely manner in people whose health is likely to improve with this modification
PROF MERLIN THOMAS DIAttitude Study INERTIA a failure to initiate or modify treatment in a timely manner in people whose health is likely to improve with this modification 13% immediately 41% of patients
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study
ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards
More informationSHORT COMMUNICATION. G. Joshy & P. Dunn & M. Fisher & R. Lawrenson
Diabetologia (2009) 52:1474 1478 DOI 10.1007/s00125-009-1380-1 SHORT COMMUNICATION Ethnic differences in the natural progression of nephropathy among diabetes patients in New Zealand: hospital admission
More informationTrends of Diabetes in Alberta
Chapter 2 Epidemiological Trends of Diabetes in Alberta Jeffrey A. Johnson Stephanie U. Vermeulen ALBERTA DIABETES ATLAS 27 11 12 ALBERTA DIABETES ATLAS 27 EPIDEMIOLOGICAL TRENDS OF DIABETES IN ALBERTA
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationDiabetes Prevention & Management of Complications
Diabetes Prevention & Management of Complications Dr Ketan Dhatariya Consultant in Diabetes and Endocrinology NNUH The Planet is Changing IFCC (mmol/mol) = (current value (%) * 10.93) - 23.50 (reported
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationType 2 Diabetes in Adolescents
Type 2 Diabetes in Adolescents Disclosures Paid consultant, Eli Lilly, Inc, Pediatric Type 2 Diabetes Clinical Trials Outline The burden of diabetes Treatment and Prevention Youth Diabetes Prevention Clinic
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationCommunity Based Diabetes Prevention
Community Based Diabetes Prevention Melanie Davies Professor of Diabetes Medicine Outline NIHR Programme Grant proposal and update to progress The Vascular Check programme HbA1c debate Algorithm to detect
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationThe prevalence and history of knee osteoarthritis in general practice: a case control study
The Author (2005). Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org doi:10.1093/fampra/cmh700 Family Practice Advance Access
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationLifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart Study
Diabetes Care Publish Ahead of Print, published online May 5, 2008 Lifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationMetabolic Syndrome: Why Should We Look For It?
021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you
More informationDiabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
More informationUnraveling the concealed and calculated cardiovascular risks in diabetes
15 P B Fernando Memorial Oration 2015 Unraveling the concealed and calculated cardiovascular risks in diabetes Weerarathna T P 1 Journal of the Ceylon College of Physicians, 2016, 47, 15-19 Abstract Cardiovascular
More informationDiabetes. Health Care Disparities: Medical Evidence. A Constellation of Complications. Every 24 hours.
Health Care Disparities: Medical Evidence Diabetes Effects 2.8 Million People in US 7% of the US Population Sixth Leading Cause of Death Kenneth J. Steier, DO, MBA, MPH, MHA, MGH Dean of Clinical Education
More informationNHS Greater Glasgow & Clyde Managed Clinical Network for Diabetes
Guidelines for the Diagnosis of Diabetes Mellitus NHS Greater Glasgow & Clyde Managed Clinical Network for Diabetes Lead Authors: Dr Brian Kennon, Dr David Carty June 2015 Review due: December 2016 Diagnosis
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationDYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul Rashid
Malaysian Journal of Medical Sciences, Vol. 11, No. 1, January 2004 (44-51) ORIGINAL ARTICLE DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul
More informationProfessional development requirements for delivery of Lift for Life
Professional development requirements for delivery of Lift for Life Exercise Professionals can deliver the Lift for Life program beyond the initial two year approval period if they are to meet the following
More informationPREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS
PREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS Mehmet Emre Atabek,MD,PhD Necmettin Erbakan University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology and
More informationDiagnosis and Management of Type 2 Diabetes Mellitus in Adults
Quality Improvement Support: Diagnosis and Management of Type 2 Diabetes Mellitus in Adults The Aims and Measures section is intended to provide guideline users with a menu of measures for multiple purposes,
More informationDr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead
Dr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead Today s Presentation HbA1c & diagnosing Diabetes What is Impaired Glucose & IGR? Implications
More informationADHD and Adverse Health Outcomes in Adults
Thomas J. Spencer, MD This work was supported in part by a research grant from Shire (Dr. Spencer) and by the Pediatric Psychopharmacology Council Fund. Disclosures Dr. Spencer receives research support
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationDiabetes mellitus is diagnosed and characterized by chronic hyperglycemia. The effects of
Focused Issue of This Month Early Diagnosis of Diabetes Mellitus Hyun Shik Son, MD Department of Internal Medicine, The Catholic University of Korea College of Medicine E - mail : sonhys@gmail.com J Korean
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationAlthough the prevalence and incidence of type 2 diabetes mellitus
n clinical n Validating the Framingham Offspring Study Equations for Predicting Incident Diabetes Mellitus Gregory A. Nichols, PhD; and Jonathan B. Brown, PhD, MPP Background: Investigators from the Framingham
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationScottish Diabetes Survey 2012
Scottish Diabetes Survey 2012 Scottish Diabetes Survey Monitoring Group 1 Scottish Diabetes Survey Monitoring Group Contents Foreword... 3 Executive Summary... 5 Prevalence... 6 Undiagnosed diabetes...
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationGetting serious about preventing cardiovascular disease
Getting serious about preventing cardiovascular disease Southwark s Experience Professor Kevin Fenton Director of Health and Wellbeing, London Borough of Southwark February 2018 Twitter: @ProfKevinFenton
More informationObjectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015
Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationPreliminary Report July 2018
Preliminary Report July 2018 Authors Emma Sainsbury Research Officer, The Boden Institute, Faculty of Medicine & Health, University of Sydney Yumeng Shi Research Officer, The Boden Institute, Faculty of
More informationTitle: Estimates and Projections of Prevalence of Type Two Diabetes Mellitus in the US 2001, 2011, 2021: The Role of Demographic Factors in T2DM.
Title: Estimates and Projections of Prevalence of Type Two Diabetes Mellitus in the US 2001, 2011, 2021: The Role of Demographic Factors in T2DM. Proposed PAA Session: 410: Obesity, Health and Mortality
More informationDiabetologia 9 Springer-Verlag 1991
Diabetologia (1991) 34:590-594 0012186X91001685 Diabetologia 9 Springer-Verlag 1991 Risk factors for macrovascular disease in mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease
More informationFrequency of Dyslipidemia and IHD in IGT Patients
Frequency of Dyslipidemia and IHD in IGT Patients *Islam MS, 1 Hossain MZ, 2 Talukder SK, 3 Elahi MM, 4 Mondal RN 5 Impaired glucose tolerance (IGT) is often associated with macrovascular complications.
More informationEffectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2009 Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
More informationObesity and Insulin Resistance According to Age in Newly Diagnosed Type 2 Diabetes Patients in Korea
https://doi.org/10.7180/kmj.2016.31.2.157 KMJ Original Article Obesity and Insulin Resistance According to Age in Newly Diagnosed Type 2 Diabetes Patients in Korea Ju Won Lee, Nam Kyu Kim, Hyun Joon Park,
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationNational Paediatric Diabetes Audit
National Paediatric Diabetes Audit Parent and Carers Report 2014-15 Commissioned by the Healthcare Quality Improvement Partnership Managed by the Royal College of Paediatrics and Child Health 2 National
More informationGlycemic Control Patterns and Kidney Disease Progression among Primary Care Patients with Diabetes Mellitus
ORIGINAL RESEARCH Glycemic Control Patterns and Kidney Disease Progression among Primary Care Patients with Diabetes Mellitus Doyle M. Cummings, PharmD, Lars C. Larsen, MD, Lisa Doherty, MD, MPH, C. Suzanne
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,
More informationBEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS
BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High
More informationScottish Diabetes Survey
Scottish Diabetes Survey 2008 Scottish Diabetes Survey Monitoring Group Foreword The information presented in this 2008 Scottish Diabetes Survey demonstrates a large body of work carried out by health
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationCardiovascular Risk in Metabolically Healthy and Unhealthy Obese Nigerians
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861. Volume 13, Issue 5 Ver. III. (May. 2014), PP 72-76 Cardiovascular Risk in Metabolically Healthy and Unhealthy
More informationUniversity of Bristol - Explore Bristol Research
Brownrigg, J. R. W., Hughes, C. O., Burleigh, D., Karthikesalingam, A., Patterson, B. O., Holt, P. J.,... Hinchliffe, R. J. (2016). Microvascular disease and risk of cardiovascular events among individuals
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationCopyright. Ayoade Olayemi Adeyemi
Copyright By Ayoade Olayemi Adeyemi 2011 The Thesis Committee for Ayoade Olayemi Adeyemi Certifies that this is the approved version of the following thesis: Adherence to oral antidiabetic medications
More informationDiabetes Control and Complications in Public Hospitals in Malaysia
ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationPage 1. Disclosures. Background. No disclosures
Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationA study on clinical profile of acute coronary syndrome in type 2 diabetes mellitus patients with relevance to HbA1c
Original Research Article A study on clinical profile of acute coronary syndrome in type 2 diabetes mellitus patients with relevance to HbA1c K. Babu Raj 1, G. Sivachandran 2* 1 Reader, 2 Final Year Post
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More information